Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring-Reference-Cited by-同舟云学术

Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring

Published:2007-09-13 Issue:3 Volume:22 Page:641-644
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

van der Velden V H J,Wijkhuijs J M,van Dongen J J M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404925.pdf

Reference8 articles.

1. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604–611.

2. van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706–713.

3. van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.

4. van Wering ER, van der Linden-Schrever BE, Szczepanski T, Willemse MJ, Baars EA, van Wijngaarde-Schmitz HM et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol 2000; 110: 139–146.

5. van Lochem EG, Wiegers YM, van den Beemd R, Hahlen K, van Dongen JJM, Hooijkaas H . Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia 2000; 14: 688–695.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?;Leukemia;2024-09-10

2. The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category;Leukemia;2024-05-17

3. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines;Leukemia;2024-05-14

4. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia;New England Journal of Medicine;2023-04-27

5. Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia;Frontiers in Oncology;2023-01-16